ストックスクリーナーアプリを入手
0.449
4.31%
-0.0202
プレマーケット:
.46
0.011
+2.45%
Scilex Holding Company (SCLX) 最新ニュース
Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication - Yahoo Finance Australia
Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024 - The Manila Times
Scilex Holding Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Scilex Holding Company (SCLX) reports earnings - Quartz
Jane Street Group LLC Trims Position in Scilex Holding (NASDAQ:SCLX) - Defense World
Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults - Yahoo Finance
Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch - The Manila Times
Scilex (NASDAQ:SCLXW) Trading Up 22.5% – Here’s Why - Defense World
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination - The Manila Times
Thinking about buying stock in Scilex Holding, iCoreConnect, Genius Group, Helius Medical Technologies, or TradeUP Acquisition? - Marketscreener.com
**Scilex Holding Co Changes Record Date for Dividend Payment**** - Defense World
Scilex Adjusts Record Date for Preferred Stock Dividend - TipRanks
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, - The Manila Times
Scilex Holding Shifts Semnur Pharmaceuticals Dividend Record Date to January 2025, Updates Preferred Stock Distribution - StockTitan
Scilex Holding (NASDAQ:SCLX) Short Interest Down 14.0% in December - Defense World
Scilex Holding (NASDAQ:SCLX) Sees Large Decline in Short Interest - MarketBeat
State Street Corp Buys 54,404 Shares of Scilex Holding (NASDAQ:SCLX) - Defense World
Scilex (NASDAQ:SCLXW) Shares Up 4.7% – What’s Next? - Defense World
Scilex CEO Jaisim Shah buys $13,800 in company stock By Investing.com - Investing.com South Africa
Scilex CEO Jaisim Shah buys $13,800 in company stock - Investing.com India
Jaisim Shah Purchases 30,000 Shares of Scilex Holding (NASDAQ:SCLX) Stock - MarketBeat
SCLX stock touches 52-week low at $0.46 amid market challenges - Investing.com
Scilex Holding Co options imply 15.0% move in share price post-earnings - TipRanks
Palo Alto pharmaceutical company secures $17M - The Business Journals
Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation - The Manila Times
Scilex Holding Company Announces Early Installment Payment - GlobeNewswire
Scilex Holding Company closes registered direct offering - Medical Buyer
Holding Company Shares Rally Following Board Of Directors Commentary - MSN
Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering - The Manila Times
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - The Eastern Progress Online
Scilex completes $17 million direct stock and warrant offering - Investing.com
Scilex Holding Co options imply 17.2% move in share price post-earnings - TipRanks
Scilex secures $17 million in stock and warrant sale - Investing.com
Scilex Holding Company Announces $17 Million Registered Direct Offering - The Manila Times
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - The Manila Times
Scilex Bio says KDS201 currently enrolling with U.S. patient cohort to be added - TipRanks
Scilex Bio, a Controlling Interest of Joint Venture by - GlobeNewswire
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - Yahoo Finance
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials C - The Manila Times
NeuroBiogen Company and Scilex Bio Enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 - Marketscreener.com
SCLX: Deal Brings Huge Potential - Research Tree
Scilex Holding agrees to share sale to meet debt obligations By Investing.com - Investing.com Nigeria
Scilex Holding agrees to share sale to meet debt obligations - Investing.com
Scilex Announces Joint Venture for CNS Compound Development - TipRanks
NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes C - The Manila Times
NeuroBiogen Company and Scilex Bio, a Controlling Interest - GlobeNewswire
Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and - The Manila Times
Scilex and IPMC announce joint venture for obesity drug By Investing.com - Investing.com UK
Scilex Holding Company Enters into a Binding Term Sheet for - GlobeNewswire
Walmart Inc (WMT-N) QuotePress Release - The Globe and Mail
Short Interest in Scilex Holding (NASDAQ:SCLX) Decreases By 51.1% - MarketBeat
Scilex Holding Co reaches agreement to waive default penalties By Investing.com - Investing.com South Africa
0.21%
0.72%
大文字化:
|
ボリューム (24 時間):